UCB (OTCMKTS:UCBJF) Shares Gap Up – Should You Buy?

UCB SA (OTCMKTS:UCBJF)’s share price gapped up prior to trading on Wednesday . The stock had previously closed at $267.3125, but opened at $286.25. UCB shares last traded at $286.25, with a volume of 1 shares changing hands.

Wall Street Analyst Weigh In

UCBJF has been the topic of several recent research reports. Morgan Stanley reiterated an “overweight” rating on shares of UCB in a report on Monday, September 8th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of UCB in a report on Monday, October 6th. Two equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, UCB currently has an average rating of “Buy”.

UCB Stock Performance

The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The firm has a 50-day moving average of $274.24 and a 200-day moving average of $230.79.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.